Table S4. from Clinical Validity of FoundationOne Liquid CDx for Detection of BRAFV600E in Colorectal Cancer

Puntos clave

• The analysis shows significant clinical validity of FoundationOne Liquid CDx for detecting BRAF V600E.
• Post-imputation data reveal a positive predictive value (PPV) and percentage agreement (PPA) in colorectal cancer testing.
• Data were analyzed to assess the accuracy of BRAF detection, enhancing the clinical decision-making process.
• The findings suggest that FoundationOne Liquid CDx could improve testing strategies for colorectal cancer patients.